Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 15/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275485 | 1.00 | ACLY (0.61) | ACLYKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2255853 | 0.93 | KMT2A (0.56) | ACLYKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2255856 | 0.93 | KMT2A (0.56) | ACLYKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL27716659 | 0.86 | KMT2A (0.62) | KMT2AKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2273406 | 0.84 | PTGES2 (0.47) | ACLYKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2271253 | 0.84 | PTGES2 (0.47) | ACLYKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL13561005 | 0.83 | KMT2A (0.60) | KMT2AKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2269088 | 0.81 | CYP2C9 (0.58) | KMT2AKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2269092 | 0.81 | CYP2C9 (0.58) | KMT2AKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2271008 | 0.81 | KMT2A (0.56) | ACLYKMT2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885KMT2A 1669/4885KDM4E 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.